Sabe Marwa A, Jacob Miriam S, Taylor David O
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA. E-mail:
Cleve Clin J Med. 2015 Oct;82(10):693-701. doi: 10.3949/ccjm.82a.14163.
The PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) found a combination drug containing sacubitril (a neprilysin inhibitor) and valsartan (an angiotensin II receptor blocker) superior to enalapril (an angiotensin-converting enzyme inhibitor) in patients with systolic heart failure. Recently approved by the US Food and Drug Administration, sacubitril-valsartan is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.
PARADIGM-HF试验（比较ARNI与ACEI对心力衰竭全球死亡率和发病率影响的前瞻性研究）发现，对于收缩性心力衰竭患者，一种包含沙库巴曲（一种中性肽链内切酶抑制剂）和缬沙坦（一种血管紧张素II受体阻滞剂）的复方药物优于依那普利（一种血管紧张素转换酶抑制剂）。沙库巴曲缬沙坦最近已获美国食品药品监督管理局批准，是十多年来首个降低收缩性心力衰竭患者死亡率的新药。
